315 related articles for article (PubMed ID: 37487943)
1. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.
Liu Y; Lu J; Zhan H; Yuan W; Li X; Kang H; Li H; Chen Y; Cheng L; Sun X; Zheng H; Wang W; Dai E; Li Y
Virol Sin; 2023 Oct; 38(5):723-734. PubMed ID: 37487943
[TBL] [Abstract][Full Text] [Related]
2. Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV.
Zhan H; Gao H; Liu Y; Zhang X; Li H; Li X; Wang L; Li C; Li B; Wang Y; Dai E; Li Y
J Med Virol; 2023 Jan; 95(1):e28428. PubMed ID: 36571267
[TBL] [Abstract][Full Text] [Related]
3. Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization.
Chen C; Dai L; Zheng C; Li H; Li X; Yang M; Gao R; Yao J; Zhang Z; Shi Y; Han X
J Hematol Oncol; 2023 May; 16(1):47. PubMed ID: 37138279
[TBL] [Abstract][Full Text] [Related]
4. Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease.
Song R; Yang C; Li Q; Wang J; Chen J; Sun K; Lv H; Yang Y; Liang J; Ye Q; Gao Y; Li J; Li Y; Yan J; Liu Y; Wang T; Liu C; Zhu P; Wang F; Yin W; Xiang H
Front Immunol; 2023; 14():1200198. PubMed ID: 37398662
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to inactivated COVID-19 vaccine were decreased in Chinese patients with chronic respiratory diseases.
Yang L; Xu L; Guo Q; Deng B; Hong Y; Wang L; Wang Y; Jiang D; Ren H
Int J Med Sci; 2023; 20(6):737-748. PubMed ID: 37213672
[No Abstract] [Full Text] [Related]
6. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
7. Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: A longitudinal observational study.
Chen Z; Huang T; He T; Zha G; Zhu Q; Zhang G; Xiang D; Chen M; Li H; Ling N; Lan Y; Shi X; Zhang D; Xu P; Pan Q; Song R; Cao J; Zhang Y; Xiang H; Feng Y; Yang Z; Zhang B; Shen W; Cai D; Peng M; Hu P; Ren H
J Med Virol; 2023 Apr; 95(4):e28695. PubMed ID: 36946505
[TBL] [Abstract][Full Text] [Related]
8. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
10. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection.
Zhou Y; Chen Z; He Y; Peng X; Chang Y; Tan A; Li H; Cai D; Hu P; Chen M; Peng M; Xu H; Ren H
Front Cell Infect Microbiol; 2023; 13():1201101. PubMed ID: 37457966
[TBL] [Abstract][Full Text] [Related]
13. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
[TBL] [Abstract][Full Text] [Related]
14. Antibody response to inactivated COVID-19 vaccine in patients with type 2 diabetes mellitus after the booster immunization.
Li H; Wang Y; Li X; Wang S; Feng X; Xiao X; Li Y
J Diabetes; 2023 Nov; 15(11):931-943. PubMed ID: 37518861
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination.
Gao R; Zheng C; Yang M; Dai L; Chen C; Yao J; Zhang Z; Tang L; Shi Y; Han X
Expert Rev Vaccines; 2023; 22(1):1102-1113. PubMed ID: 37878494
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
[TBL] [Abstract][Full Text] [Related]
17. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination.
Liang B; Xiang T; Wang H; Li Z; Quan X; Feng X; Li S; Lu S; Fan L; Xu L; Wang T; Wang X; Zhu B; Wang J; Yang D; Liu J; Zheng X
Front Immunol; 2022; 13():966098. PubMed ID: 35979361
[TBL] [Abstract][Full Text] [Related]
18. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
[TBL] [Abstract][Full Text] [Related]
19. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
